Sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes (T2D) have consistently demonstrated renal and cardiovascular (CV) benefit, the latter especially for heart failure–related (HF-related) events (1–6). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.